Dublin, May 12th, 2021– Nemysis Ltd. today announced the issuance of China Patent Number 201680058940.3 titled “Methods for producing carboxylate ligand modified ferric iron hydroxide colloids and related compositions and uses”. This is the first patent issued to Nemysis in China in the field of oral iron supplementation in conditions of ID and IDA. The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin – the dietary and iron storage form of iron – increasing iron availability upon increased iron demand by the body.

IHAT is well absorbed by endocytosis exclusively into duodenal enterocytes, does not release free iron on the intestinal lining and, as such, does not exert a negative impact on the gut, as per most oral iron supplementation products currently available on the market. Absorption studies and nutritional trials in humans demonstrate IHAT to be efficiently absorbed and to correct markers of ID and IDA, with no burden of gastrointestinal side effects and no disruption of the gut microbiome.

Danilo Casadei-Massari, Chairman and CEO of Nemysis Ltd commented, “We are particularly excited about the grant of this Patent. This patent further supports our ongoing R&D efforts in treating a worldwide highly prevalent condition such as ID and IDA, with a product representing the crest of the wave of innovation in the field of iron supplementation.

Marco Cartolari, COO of Nemysis Ltd added “The Grant of our first China Patent is a great moment for Nemysis. We are excited to bring IHAT and help those who are affected by iron deficiency in China.  Receipt of this patent reflects our continued focus on innovation while strengthening our international intellectual property portfolio, and covers a product that we believe has significant market potential.”

About Nemysis:

NEMYSIS LTD, healthcare and pharmaceutical company focused on nutritional and pharmaceutical solutions that can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose clinical trials.

Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

www.nemysisltd.com

Danilo Casadei-Massari

Chairman of the Board

Nemysis Ltd

7 D’Olier Street

D02HF60 Dublin

Ireland

+35315313450

casadei-massari@nemysisltd.com

DUBLIN, April 23, 2021  – Nemysis Ltd today announces the appointment of internationally recognized drug discovery and development expert Linda Cavaletti to its Scientific Advisory Board (SAB).

Since its inception, Nemysis has initiated and developed high-value innovative R&D programs, including one targeting Celiac Disease and Non-Celiac Gluten intolerance, with the aim of bringing novel treatments to patients suffering from these conditions.

Linda Cavaletti, Senior Associate Scientist at Fondazione Istituto Insubrico di Ricerca per la Vita (FIIRV), is a biologist with long expertise in isolation and cultivation of strains for natural products discovery, culminating in a project for identification of a new glutenase by acidophilic actinomycete strains. Since then, she is the leader of the Celiac Disease project in FIIRV, which led to discovery of E40, its patenting in 2012, and the collaboration with Nemysis.

“I am delighted to join Nemysis’s board of Scientific Advisors and eager to contribute to Nemysis’ corporate development efforts to realize its vision on E40,” said Linda Cavaletti. “I believe the company’s prospects are excellent. I look forward to working with the team over the coming years to build a broad-based, world-class company.”

“We are very honoured and privileged to have established this long-term collaboration with such an expert on enzyme development, who we are sure will be a valuable asset to Nemysis and to those who suffer from gluten intolerance,” said Maria Cristina Comelli, chair of the SAB. “We are excited about working closely with her, as we approach the next phase of our company’s growth.”

“I am personally very pleased to welcome such an outstanding scientist as an advisor to Nemysis,” said Danilo Casadei-Massari, Chairman of the Board. “No doubt Linda Cavaletti’s expertise will contribute to increasing the value of Nemysis’s current and future assets.”

About Nemysis:

NEMYSIS LTD, a healthcare and pharmaceutical company, is focused on nutritional and pharmaceutical solutions that can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

• Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose clinical trials.
• Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

www.nemysisltd.com

Danilo Casadei-Massari, Chairman of the Board

Nemysis Ltd – 7 D’Olier Street- D02HF60 Dublin – Ireland +35315313450

casadei-massari@nemysisltd.com

Nemysis Limited, the Dublin based pharmaceutical and healthcare company, focused on Iron Deficiency/Anemia and Gluten Sensitivity, today announced that the South Africa Patent and Trademark Office has issued S.A. Patent No.ZA201802192, with claims of Methods for Producing Carboxylate Ligand Modified Ferric Iron Hydroxide Colloids and Related Compositions and Uses, directed to the use of oral iron supplementation.

“This is an advancement in our efforts to broaden our global patent estate for IHAT,” said Danilo Casadei-Massari, Chairman and Chief Executive Officer of Nemysis. “To date, our intellectual property portfolio spans multiple patents and patent applications in the U.S., EU, and numerous additional countries.”

Currently, the research-based company, Nemysis has several patents approved and filed in the U.S., EU and other countries around the world, related to its IHAT, novel oral iron formulation, to support the company’s effort to establish and protect a global commercial footprint in the near future.

About Nemysis:

NEMYSIS LTD, a healthcare and pharmaceutical company, is focused on nutritional and pharmaceutical solutions that can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose clinical trials.

Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

www.nemysisltd.com

Danilo Casadei-Massari

Chairman of the Board

Nemysis Ltd

7 D’Olier Street

D02HF60 Dublin

Ireland

+35315313450

casadei-massari@nemysisltd.com

DUBLIN, May 22, 2020 –​​Nemysis Limited, the Dublin-based pharmaceutical and healthcare company, announced that it opened the Italian subsidiary Nemysis S.r.l.

Currently, Nemysis has three high-potential products in its development pipeline and, preparing to the market presence is the next crucial step in the expansion strategy of the company.

​Danilo Casadei-Massari, Chairman and CEO of Nemsysis Ltd, believes that Italy can serve as a launchpad for future developments in Europe: “I am delighted that Nemysis has a continental Europe subsidiary now. Nemysis is looking forward to working in Italy as the well – established clinical expertise in the country adds important value to our R&D efforts and specifically our expeditious development of E40.”

Heading the Italian office will be Marco Cartolari – CEO of Nemysis S.r.l.- who, through his experience as CEO of Scharper Pharmaceuticals S.p.A., pioneered the nutraceutical market in Italy. Marco has deep expertise in bringing this class of products from the research stage into the market.

An integral part of Nemysis’ strategy is to cultivate and grow the company’s relationship with the Italian scientific community. According to Cartolari, “Italy represents one of the most developed food supplement markets, and the medical community is particularly open to the use of non-drug products to help patients, but only if backed by highly scientific validation. Our novel food products will fit this approach and establish new standards of quality in the nutraceutical market.”

Given the depth of experience in the Italian market by Nemysis’ management team, as well as the strong growth rates of the nutraceutical products market, Italy represents a unique opportunity for Nemysis’ commercial strategy.

About Nemysis:

Nemysis Ltd, a healthcare and pharmaceutical company, is focused on nutritional and pharmaceutical solutions which can protect against some of the negative consequences of nutrient deficiency, nutrient intolerances and sensitivities, paying particular attention to the need to safeguard the human microbiome.

• Nemysis’s novel nanoparticulate iron is the first natural ferritin mimic, which can correct human iron deficiency and anemia, without negatively impacting the gut microbiome. Safety and efficacy have been demonstrated in controlled-repeat-dose [clinical] trials.
• Nemysis’s novel E40 endopeptidase is gastric, trypsin and chymotrypsin resistant. It has been shown to destroy all the immuno-stimulatory epitopes of gluten, quenching the exacerbated inflammatory response of primed, gluten-sensitive and hyper-responsive human T cells. It is, therefore, suitable for the enzymatic management of gluten intolerance and sensitivity.

·         Nemysis has three further products in its pipeline for use in Iron Deficiency/Anaemia, Gluten sensitivity and Celiac Disease

Find out more   www.nemysisltd.com

Release date: May 22, 2020

Contact information

Danilo Casadei -Massari

Chairman of the Board

Nemysis Ltd

7 D’Olier Street

D02HF60 Dublin

Ireland

+35315313450

casadei-massari@nemysisltd.com

Nemysis Limited, the Dublin-based pharmaceutical and healthcare Company focused on iron deficiency/anemia and gluten sensitivity has announced that it has completed a €2.65M capital raise.